Should You Buy Pain Therapeutics, Inc. (PTIE)?: Cytokinetics, Inc. (CYTK), ArQule, Inc. (ARQL)

Pain Therapeutics, Inc. (NASDAQ:PTIE) has experienced an increase in hedge fund interest of late.

Pain Therapeutics, Inc. (NASDAQ:PTIE)

In today’s marketplace, there are a multitude of gauges investors can use to track their holdings. A couple of the most under-the-radar are hedge fund and insider trading movement. At Insider Monkey, our research analyses have shown that, historically, those who follow the best picks of the top fund managers can trounce the S&P 500 by a solid amount (see just how much).

Just as beneficial, optimistic insider trading activity is another way to parse down the stock market universe. As the old adage goes: there are plenty of incentives for a corporate insider to downsize shares of his or her company, but just one, very obvious reason why they would buy. Plenty of empirical studies have demonstrated the useful potential of this method if piggybackers know where to look (learn more here).

With these “truths” under our belt, let’s take a peek at the key action encompassing Pain Therapeutics, Inc. (NASDAQ:PTIE).

What have hedge funds been doing with Pain Therapeutics, Inc. (NASDAQ:PTIE)?

Heading into 2013, a total of 11 of the hedge funds we track were bullish in this stock, a change of 10% from one quarter earlier. With the smart money’s sentiment swirling, there exists a few notable hedge fund managers who were increasing their holdings meaningfully.

Of the funds we track, Jacob Gottlieb’s Visium Asset Management had the most valuable position in Pain Therapeutics, Inc. (NASDAQ:PTIE), worth close to $12 million, comprising 0.4% of its total 13F portfolio. The second largest stake is held by Steven Owsley of Madison Street Partners, with a $5 million position; 0% of its 13F portfolio is allocated to the stock. Other hedgies that are bullish include Howard Guberman’s Gruss Asset Management, Jim Simons’s Renaissance Technologies and Jean-Marie Eveillard’s First Eagle Investment Management.

As industrywide interest jumped, some big names have jumped into Pain Therapeutics, Inc. (NASDAQ:PTIE) headfirst. Citadel Investment Group, managed by Ken Griffin, created the largest position in Pain Therapeutics, Inc. (NASDAQ:PTIE). Citadel Investment Group had 0 million invested in the company at the end of the quarter. Ken Griffin’s Citadel Investment Group also made a $0 million investment in the stock during the quarter.

What do corporate executives and insiders think about Pain Therapeutics, Inc. (NASDAQ:PTIE)?

Bullish insider trading is best served when the company in question has seen transactions within the past half-year. Over the last half-year time frame, Pain Therapeutics, Inc. (NASDAQ:PTIE) has experienced zero unique insiders purchasing, and zero insider sales (see the details of insider trades here).

Let’s also take a look at hedge fund and insider activity in other stocks similar to Pain Therapeutics, Inc. (NASDAQ:PTIE). These stocks are Cytokinetics, Inc. (NASDAQ:CYTK), ArQule, Inc. (NASDAQ:ARQL), ZIOPHARM Oncology Inc. (NASDAQ:ZIOP), BioDelivery Sciences International, Inc. (NASDAQ:BDSI), and Amicus Therapeutics, Inc. (NASDAQ:FOLD). This group of stocks belong to the biotechnology industry and their market caps match PTIE’s market cap.

Company Name # of Hedge Funds # of Insiders Buying # of Insiders Selling
Cytokinetics, Inc. (NASDAQ:CYTK) 7 0 1
ArQule, Inc. (NASDAQ:ARQL) 13 0 0
ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) 6 1 0
BioDelivery Sciences International, Inc. (NASDAQ:BDSI) 9 2 2
Amicus Therapeutics, Inc. (NASDAQ:FOLD) 8 2 0

With the returns exhibited by our strategies, retail investors should always monitor hedge fund and insider trading activity, and Pain Therapeutics, Inc. (NASDAQ:PTIE) is no exception.

Click here to learn why you should track hedge funds

Comments
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months. Our beta is only 1.2 (don't click this link if beating the market isn't important to you).

Lists

The 10 Largest Pharmaceutical Companies In the World

The 10 Most Expensive Android Apps

The 9 Most Expensive Designer Bags in the World

The 7 Most Expensive Real Estate in the World

The 10 Most Expensive eBay Items Ever Sold

The 10 Most Expensive iPhone Apps

The 9 Most Expensive Designer Shoes in the World

The 10 Most Expensive Cigarette Brands

The 10 Most Expensive Law Schools in the US

The 10 Best Wall Street Movies

The 10 Most Expensive Golf Clubs Ever Sold

The 10 Most Expensive Golf Memberships

The 10 Best Disney Characters Ever Created

The 8 Best Foods for Gaining Weight

The 10 Most Expensive Colleges in the World

The 7 Most Memorable Ad Campaigns of All Time

The 7 Most Expensive High Schools in the World

The 10 Electric Vehicles with the Longest Range

The 10 Cities with the Worst Drivers in the World

The 10 Most Expensive Dresses Ever Created

10 Islands to Visit Before You Die

10 Famous Celebrities Who Needed Rehab

The 15 Countries with the Largest Oil Reserves

The 10 Most Overused Excuses in the World

The 5 Best iOS Apps You Can’t Get on Android

5 Companies Damaged By Social Media Blunders

The 10 Most Legendary Blues Songs

The 10 Most Lawless Places in the World

4 Reasons China is a Threat to the US

The 17 Most Sugary Drinks in the World

The 10 Most Ruthless Rulers in History

The 10 Greatest Generals in History

Top 8 Travel Destinations for 2015

The 10 Safest Dog Breeds for Children

The 10 Most Stolen Vehicles in the US

The 7 Most Expensive Celebrity Weddings

The 10 Best LoL Teams in the World

Top 10 Worst Marketing Campaigns Ever Produced

Top 5 Diets that Help You Lose Weight

The 10 Best Ways to Stay Awake

7 Artists That Switched Musical Genres

The 10 Most Expensive Cities to Live in New Jersey

The 10 Best High Schools in New York

The 10 Countries With the Least Gender Inequality

The 6 Biggest Musician-Manager Feuds

The 10 Countries with the Cheapest Gas Prices

The 7 Most Theatrical Bands of All Time

The 8 Worst Band Breakups of All Time

The 10 Most Important South American Leaders

The 7 Most Successful Casting Show Winners

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!